Product Description
Adriforant (ZPL-3893787) was a clinical stage immunomodulatory compound being developed by Ziarco Pharma (a Novartis subsidiary). Mechanistically it is a selective histamine H4 receptor antagonist (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8985)
Mechanisms of Action: H4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic|Psoriasis
Phase 1: Healthy Volunteers|Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00992342 |
B0281003 | P1 |
Completed |
Healthy Volunteers |
2010-03-01 |
2019-03-19 |
Treatments |
|
NCT00856687 |
B0281002 | P1 |
Completed |
Asthma |
2009-12-01 |
2019-03-18 |
Treatments |
|
jRCT2080224724 |
jRCT2080224724 | P2 |
Completed |
Dermatitis, Atopic |
2022-04-30 |
|||
jRCT2080223954 |
jRCT2080223954 | P2 |
Completed |
Dermatitis, Atopic |
2021-06-30 |
|||
2018-000595-15 |
ZEST Extension | P2 |
Terminated |
Dermatitis, Atopic |
2020-08-25 |
73% |
2022-03-13 |
Treatments |
2017-002176-75 |
A study to assess the safety and efficacy of ZPL389 doses in patients with moderate to severe AD | P2 |
Terminated |
Dermatitis, Atopic |
2020-08-07 |
2022-03-13 |
Treatments |
|
NCT03948334 |
ZESTExt | P2 |
Terminated |
Dermatitis, Atopic |
2020-07-23 |
73% |
2021-07-21 |
Primary Endpoints |
NCT03517566 |
ZEST Trial | P2 |
Terminated |
Dermatitis, Atopic |
2020-07-15 |
75% |
2021-07-21 |
Patient Enrollment|Primary Endpoints |
NCT02618616 |
ZPL389/102 | P2 |
Completed |
Psoriasis |
2016-12-22 |
2021-07-21 |
Primary Endpoints|Treatments |
|
2015-003812-19 |
A Phase 2a study of oral ZPL-3893787 in adults with plaque psoriasis | P2 |
Completed |
Psoriasis |
2016-12-22 |
2022-03-13 |
Treatments |
|
2014-005057-39 |
2014-005057-39 | P2 |
Completed |
Dermatitis, Atopic |
2016-02-03 |
2022-03-13 |
Treatments |
|
NCT02424253 |
ZPL389/101 | P2 |
Completed |
Dermatitis, Atopic |
2016-01-01 |
2021-05-14 |
Primary Endpoints|Start Date|Study Completion Date|Treatments |